Gene · 10578
NIH grants2,192
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1 to 20 of 2,192
Download this page as JSON| Grant | Title | GNLY papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001863 | Yale Clinical and Translational Science Award | 21 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 18 | 2025 |
| R01AI022553 | Molecular Analysis of Host Immune Response in Leprosy | 14 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| R01AR040312 | CD1-restricted T-cell Responses in Skin | 12 | 2025 |
| P30AI110527 | Tennessee Center for AIDS Research (TN-CFAR) | 10 | 2025 |
| U19AI057229 | Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | 10 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 8 | 2025 |
| R01AR063759 | Defining the influence of RA genetic susceptibility factors on T cell antigen specificity and functional state | 8 | 2025 |
| T32AI007290 | Molecular and Cellular Immunobiology | 8 | 2025 |
| T32HG002295 | Training in Bioinformatics and Integrative Genomics | 8 | 2025 |
| R01AI093615 | The role of γδ T cells in fetal and infant immune defense against malaria | 7 | 2025 |
| R01AI152183 | Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | 7 | 2025 |
| T32AR007530 | Immunologic Mechanisms and Rheumatic Diseases | 7 | 2025 |
| U01AI154659 | NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis | 7 | 2025 |
| U19AI082630 | Durable Alteration of the Human Immune system after Infection or Immunotherapy | 7 | 2025 |
| P30AI050409 | Center for AIDS Research at Emory University | 6 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 6 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 6 | 2025 |
| P50CA121974 | Yale SPORE in Skin Cancer | 6 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10578/grants